# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant B)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** B
**Date:** 2026-03-31T10:09:59.122596

---

**Idea Fidelity**

The manuscript largely adheres to the original idea archive. It leverages the staggered state-level CMS opt-outs for CRNA physician supervision, utilizes the QWI state-level data, focuses on BA+ workers in NAICS 621, and emphasizes the quasi-experimental DiD/DDD strategy with both C-S and Sun–Abraham estimators, plus placebos. However, the paper diverges in one respect: whereas the manifest envisioned a DDD leveraging (Ambulatory – Hospital) × (Opt-out – Never), the manuscript’s DDD compares industries within the same specification but does not fully exploit the explicit triple-differencing structure suggested (i.e., it simply interacts OptOut with the Ambulatory indicator, rather than presenting a full 3-way interaction). While this is a minor framing difference, clarifying that the DDD absorbs hospital trends through state-industry and year-industry fixed effects would align the manuscript more tightly with the original plan.

**Summary**

The paper tests whether CMS’s staggered opt-outs from the physician supervision requirement for CRNAs shifted BA+ employment in ambulatory care. Using QWI data from 1998–2023, and four estimators addressing heterogeneous treatment timing (TWFE, Callaway–Sant’Anna, Sun–Abraham, and a within-state industry DDD), it finds precisely estimated null effects on ambulatory BA+ employment, earnings, and hires, concluding that the federal supervision mandate was non-binding. Placebo estimates for non-BA workers and unrelated industries reinforce this “supervision illusion.”

**Essential Points**

1. **Interpretation of Null Results Requires More Nuance**  
   The paper concludes that the CMS supervision rule was non-binding because nothing changed post-opt-out. Yet the null can arise from offsetting mechanisms (e.g., CRNAs gained autonomy but reduced hours, or they expanded into services not captured by NAICS 621). Without bounding such alternatives, it is premature to assert the regulation was purely ceremonial. The authors should discuss and, if possible, rule out macro-level compositional changes (e.g., using additional industries or hours metrics) to substantiate the “non-binding” claim.

2. **Heterogeneity and Power Arguments Need Refinement**  
   The paper argues that the analysis is well-powered to detect meaningful impacts, but the reported standard errors (especially for TWFE and C-S) are large relative to the point estimates. The “tight bounds” claim requires a formal power calculation or interpretation showing that plausible policy-relevant effects (for instance, a 5–10% employment increase) are statistically rejected. Otherwise, the null might simply reflect noisy data rather than an economically small effect. A sensitivity/power analysis (e.g., minimum detectable effect sizes given the sample) would clarify this.

3. **Potential Spillovers and Control Choices Require Justification**  
   The never-treated states include densely populated markets (e.g., NY, FL, TX), while treated states skew rural. This raises concerns about parallel trends: even if pre-trends look similar, the control group may not capture the counterfactual ambulatory sector dynamics (e.g., due to differential trends in outpatient surgery adoption). The authors should provide balance checks or covariate-augmented specifications (e.g., controlling for state GDP, demographics, or health-care capacity) to strengthen the credibility of the parallel-trends assumption. Without this, the null could reflect differential trends unrelated to opt-out status.

If more than three issues are necessary, I would recommend rejection, but these three are addressable.

**Suggestions**

- **Disaggregate the BA+ Group where Possible:** While QWI lacks occupation-level granularity, the authors could consider exploiting alternative data (e.g., the Bureau of Labor Statistics’ Occupational Employment Statistics or Medicare billing data) to isolate CRNAs. Even if imperfect, augmenting the main analysis with auxiliary evidence on CRNA counts would reduce reliance on the BA+ proxy. If other data are unavailable, consider clarifying in the paper why substitution within the BA+ group is unlikely by discussing workforce trends for NPs/PAs over the same period.

- **Expand on the Triple-Difference Interpretation:** The presented DDD interacts OptOut with an ambulatory indicator, but the narrative frames it as a (Ambulatory – Hospital) difference. Explicitly write out the full triple-interaction specification, and, if feasible, report the implied difference-in-differences for hospitals versus ambulatory care. This would help readers understand how hospital trends absorb general health-care labor shifts.

- **Add Event-Study Plots or More Detailed Pre-Trend Diagnostics:** The paper references “available from the author” event studies showing clean pre-trends, but the main text lacks figures. Even a concise figure with treated vs. control means or the dynamic coefficients from the Callaway–Sant’Anna estimator would enhance transparency and reassure readers about parallel trends.

- **Improve Precision on Mechanisms for the “Supervision Illusion”:** The discussion identifies institutional substitution, care-team inertia, and payer contracts as explanations. These are plausible but speculative. Consider incorporating descriptive evidence—e.g., quoting percentages of hospitals maintaining physician oversight post-opt-out, or citing audits showing credentialing bylaws remained unchanged—to substantiate the mechanism claims. Alternatively, survey or interview evidence from administrators would be compelling, though not required for the current empirical scope.

- **Consider Additional Robustness to Timing Assumptions:** While the Leave-One-Wave-Out exercise is helpful, the analysis could be strengthened by allowing for dynamic treatment effects ( leads/lags in the event study) or testing for anticipation effects (e.g., if states signaled intent to opt out before official action). Showing that pre-treatment coefficient estimates are near zero would complement the already referenced—but unshown—event study.

- **Incorporate Additional Control Variables or Synthetic Controls:** Since treated and untreated states differ systematically, including time-varying covariates (e.g., state population, number of surgical facilities, Medicare reimbursement rates) or exploring a synthetic control for a subset of treated states may help isolate the policy effect from broader secular trends in ambulatory care expansion.

- **Address Potential Nonlinear Effects:** If the effect of opt-out differed by rurality or baseline anesthesia supply, consider subgroup analysis (e.g., by quartiles of county-level CRNA density or rural population share). Even if these analyses remain null, they would reinforce the main finding by showing that the null holds across heterogeneous policy environments.

- **Clarify the Role of Private-Sector Constraints:** The argument that private credentialing made the federal rule redundant is central to the paper’s narrative. Including more formal tests—perhaps exploiting variation in hospital ownership (which may differ in credentialing rigidity) or county-level surgical center density—could tie the mechanism more directly to observable data.

- **Explicitly Address Standard Error Conservatism:** With 51 clusters, inference is delicate. Consider using wild bootstrap standard errors or reporting alternative inference methods (e.g., Ibragimov–Mueller) to ensure the null is not an artifact of conservative clustering. Even if results remain similar, this would reassure readers.

These suggestions aim to deepen the paper’s empirical credibility and strengthen its narrative without requiring a wholesale redesign.
